Unraveling the role of CD24 in Hepatocellular carcinoma : Involvement of inactivated Hippo signaling and SOX4-mediated regulation
Copyright © 2024 Elsevier B.V. All rights reserved..
Hepatocellular carcinoma (HCC) is a prevalent type of liver cancer, and CD24 gene is reportedly involved in HCC progression. However, the precise regulatory mechanisms of CD24 in HCC remain unclear. In this study, we established a primary HCC mouse model and observed that CD24, induced by inactivation of the Hippo pathway, was highly expressed in HCC. Using a systematic molecular and genomic approach, we identified the Hippo-YAP1-SOX4 pathway as the mechanism through which YAP1 induces CD24 upregulation in HCC cells. CD24 knockdown significantly attenuated YAP1 activation-induced HCC. These findings shed light on the link between CD24 and HCC progression, particularly in the Hippo-inactivated subclass of HCC. Therefore, CD24 may serve as a potential target for specific treatment of this HCC subclass.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1870 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta. Molecular basis of disease - 1870(2024), 4 vom: 28. Apr., Seite 167117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Xiaobai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD24 |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbadis.2024.167117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369517563 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369517563 | ||
| 003 | DE-627 | ||
| 005 | 20240408232631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbadis.2024.167117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369517563 | ||
| 035 | |a (NLM)38462024 | ||
| 035 | |a (PII)S0925-4439(24)00106-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Xiaobai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unraveling the role of CD24 in Hepatocellular carcinoma |b Involvement of inactivated Hippo signaling and SOX4-mediated regulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Hepatocellular carcinoma (HCC) is a prevalent type of liver cancer, and CD24 gene is reportedly involved in HCC progression. However, the precise regulatory mechanisms of CD24 in HCC remain unclear. In this study, we established a primary HCC mouse model and observed that CD24, induced by inactivation of the Hippo pathway, was highly expressed in HCC. Using a systematic molecular and genomic approach, we identified the Hippo-YAP1-SOX4 pathway as the mechanism through which YAP1 induces CD24 upregulation in HCC cells. CD24 knockdown significantly attenuated YAP1 activation-induced HCC. These findings shed light on the link between CD24 and HCC progression, particularly in the Hippo-inactivated subclass of HCC. Therefore, CD24 may serve as a potential target for specific treatment of this HCC subclass | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD24 | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Hippo pathway | |
| 650 | 4 | |a SOX4 | |
| 700 | 1 | |a Zhang, Yangyang |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiaoguang |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Weijiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Leixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Yeting |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Yaoqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Linjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Molecular basis of disease |d 2017 |g 1870(2024), 4 vom: 28. Apr., Seite 167117 |w (DE-627)NLM260137588 |x 1879-260X |7 nnns |
| 773 | 1 | 8 | |g volume:1870 |g year:2024 |g number:4 |g day:28 |g month:04 |g pages:167117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbadis.2024.167117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1870 |j 2024 |e 4 |b 28 |c 04 |h 167117 | ||